Schizophrenia Research
Volume 75, Issue 1 , Pages 35-44 , 1 June 2005

Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates

  • Robin Emsley

      Affiliations

    • Department of Psychiatry, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, Tygerberg 7505, Cape Town, South Africa
    • Corresponding Author InformationCorresponding author. Tel.: +27 21 9389227; fax: +27 21 9336159.
    • ,
  • H. Jadri Turner

      Affiliations

    • Department of Psychiatry, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, Tygerberg 7505, Cape Town, South Africa
    • ,
  • Piet P. Oosthuizen

      Affiliations

    • Department of Psychiatry, Faculty of Health Sciences, University of Stellenbosch, P.O. Box 19063, Tygerberg 7505, Cape Town, South Africa
    • ,
  • Jonathan Carr

      Affiliations

    • Division of Neurology, Department of Medicine, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa

Received 16 April 2004 ,Revised 23 June 2004 ,Accepted 23 June 2004.

References 

  1. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings and mechanisms. Arch. Gen. Psychiatry. 1995;52:341–351
  2. Arango C, Kirkpatrick B, Buchanan RW. Neurological signs and the heterogeneity of schizophrenia. Am. J. Psychiatry. 2000;157:560–565
  3. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Pharmacol. 1989;154:672–676
  4. Bersani G, Orlandi V, Gherardelli S, Pancheri P. Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology. 2002;35:289–295
  5. Browne S, Clarke M, Gervin M, Lane A, Waddington JL, Larkin C, et al. Determinants of neurological dysfunction in first episode schizophrenia. Psychol. Med. 2000;30:1433–1441
  6. Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 1989;27:335–350
  7. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry. 1996;53:313–319
  8. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry. 1995;152:1724–1729
  9. Chen EY, Lam LC, Chen RY, Nguyen DG. Neurological signs, age, and illness duration in schizophrenia. J. of Nerv. Ment. Dis. 1996;184:339–345
  10. Chen EY, Kwok CL, Au JW, Chen RY, Lau BS. Progressive deterioration of soft neurological signs in chronic schizophrenic patients. Acta Psychiatr. Scand. 2000;102:342–349
  11. Dazzan P, Morgan KD, Orr KG, Hutchinson G, Chitnis X, Suckling J, et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain. 2004;127:143–153
  12. Egan MF, Hyde TM, Bonomo JB, Mattay VS, Bigelow LB, Goldberg TE, et al. Relative risk of neurological signs in siblings of patients with schizophrenia. Am. J. Psychiatry. 2001;158:1827–1834
  13. Emsley R, Rabinowitz J, Torreman M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr. Res. 2003;61:47–57
  14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), Version 2. New York: New York State Psychiatric Institute, Biometrics Research; 1994;(Ref Type: Report)
  15. Flashman LA, Flaum M, Gupta S, Andreasen NC. Soft signs and neuropsychological performance in schizophrenia. Am. J. Psychiatry. 1996;153:526–532
  16. Flyckt L, Sydow O, Bjerkenstedt L, Edman G, Rydin E, Wiesel FA. Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. Psychiatry Res. 1999;86:113–129
  17. Gamlin PD. Subcortical neural circuits for ocular accommodation and vergence in primates. Ophthalmic Physiol. Opt. 1999;19:81–89
  18. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp. Commun. Psychiatry. 1994;45:38–42
  19. Griffiths TD, Sigmundsson T, Takei N, Rowe D, Murray RM. Neurological abnormalities in familial and sporadic schizophrenia. Brain. 1998;121(Pt. 2):191–203
  20. Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, Hubbard WC, et al. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am. J. Psychiatry. 1995;152:191–196
  21. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, MD: US Department of Health, Education and Welfare; 1976;Ref Type: Generic
  22. Heinrichs DW, Buchanan RW. Significance and meaning of neurological signs in schizophrenia. Am. J. Psychiatry. 1988;145:11–18
  23. Ismail B, Cantor-Graae E, McNeil TF. Neurological abnormalities in schizophrenic patients and their siblings. Am. J. Psychiatry. 1998;155:84–89
  24. Ismail BT, Cantor-Graae E, Cardenal S, McNeil TF. Neurological abnormalities in schizophrenia: clinical, etiological and demographic correlates. Schizophr. Res. 1998;30:229–238
  25. Jeste DV, Potkin SG, Sinha S, Feder S, Wyatt RJ. Tardive dyskinesia: reversible and persistent. Arch. Gen. Psychiatry. 1979;36:585–590
  26. Johnstone EC, Macmillan JF, Frith CD, Benn DK, Crow TJ. Further investigation of the predictors of outcome following first schizophrenic episodes. Br. J. Psychiatry. 1990;157:182–189
  27. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry. 1982;39:473–481
  28. Kay SR, Fizbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–267
  29. Keshavan MS, Sanders RD, Sweeney JA, Diwadkar VA, Goldstein G, Pettegrew JW, et al. Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses. Am. J. Psychiatry. 2003;160:1298–1304
  30. King DJ, Wilson A, Cooper SJ, Waddington JL. The clinical correlates of neurological soft signs in chronic schizophrenia. Br. J. Psychiatry. 1991;158:770–775
  31. Lane A, Colgan K, Moynihan F, Burke T, Waddington JL, Larkin C, et al. Schizophrenia and neurological soft signs: gender differences in clinical correlates and antecedent factors. Psychiatry Res. 1996;64:105–114
  32. Lawrie SM, Byrne M, Miller P, Hodges A, Clafferty RA, Cunningham Owens DG, et al. Neurodevelopmental indices and the development of psychotic symptoms in subjects at high risk of schizophrenia. Br. J. Psychiatry. 2001;178:524–530
  33. Leigh RJ, Zee DS. In: The Neurology of Eye Movements. vol. 2:Philadelphia: F.A. Davis; 1991;Contemporary Neurology Series, No. 23
  34. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry. 1993;50:369–376
  35. Madsen AL, Vorstrup S, Rubin P, Larsen JK, Hemmingsen R. Neurological abnormalities in schizophrenic patients: a prospective follow-up study 5 years after first admission. Acta Psychiatr. Scand. 1999;100:119–125
  36. Malla AK, Norman RM, Aguilar O, Cortese L. Relationship between neurological ‘soft signs’ and syndromes of schizophrenia. Acta Psychiatr. Scand. 1997;96:274–280
  37. Malla AK, Norman RMG, Manchanda R, Ahmed MR, Scholten D, Harricharan R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr. Res. 2002;54:231–242
  38. Marcus J, Hans SL, Lewow E, Wilkinson L, Burack CM. Neurological findings in high-risk children: childhood assessment and 5-year follow up. Schizophr. Bull. 1985;11:85–100
  39. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course?. [see comments] [published erratum appears in Biol Psychiatry 2000, (Mar 1);47(5):473] Biol. Psychiatry. 1999;46:899–907
  40. McGorry PD, Bell RC, Dudgeon PL, Jackson HJ. The dimensional structure of first episode psychosis: an exploratory factor analysis. Psychol. Med. 1998;28:935–947
  41. Merriam AE, Kay SR, Opler LA, Kushner SF, van Praag HM. Neurological signs and the positive–negative dimension in schizophrenia. Biol. Psychiatry. 1990;28:181–192
  42. Mohr F, Hubmann W, Cohen R, Bender W, Haslacher C, Honicke S, et al. Neurological soft signs in schizophrenia: assessment and correlates. Eur. Arch. Psychiatry Clin. Neurosci. 1996;246:240–248
  43. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia study. Arch. Gen. Psychiatry. 1993;50:723–733
  44. Niethammer R, Weisbrod M, Schiesser S, Grothe J, Maier S, Peter U, et al. Genetic influence on laterality in schizophrenia? A twin study of neurological soft signs. Am. J. Psychiatry. 2000;157:272–274
  45. Oosthuizen P, Emsley RA, Turner J, Keyter N. Determining the optimal dose of haloperidol in first-episode psychosis. J. Psychopharmacol. 2001;15:251–255
  46. Oosthuizen P, Emsley R, Maritz J, Turner J, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis treated with low-dose haloperidol. J. Clin. Psychiatry. 2003;64:1075–1080
  47. Ovsiew F. Bedside neuropsychiatry: eliciting the clinical phenomena of neuropsychiatric illness. In:  Yudovsky SC,  Hales RE editor. Synopsis of Neuropsychiatry. Washington, DC: American Psychiatric Press; 1994;p. 77–106
  48. Rubin P. Neurobiological findings in first admission patients with schizophrenia or schizophreniform disorder. Dan. Med. Bull. 1997;44:140–154
  49. Rubin P, Vorstrup S, Hemmingsen R, Andersen HS, Bendsen BB, Stromso N, et al. Neurological abnormalities in patients with schizophrenia or schizophreniform disorder at first admission to hospital: correlations with computerized tomography and regional cerebral blood flow findings. Acta Psychiatr. Scand. 1994;90:385–390
  50. Sanders RD, Keshavan MS, Schooler NR. Neurological examination abnormalities in neuroleptic-naive patients with first-break schizophrenia: preliminary results. Am. J. Psychiatry. 1994;151:1231–1233
  51. Sanders RD, Keshavan MS, Forman SD, Pieri JN, McLaughlin N, Allen DN, et al. Factor structure of neurologic examination abnormalities in unmedicated schizophrenia. Psychiatry Res. 2000;95:237–243
  52. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 1982;39:486–487
  53. Schroder J, Niethammer R, Geider FJ, Reitz C, Binkert M, Jauss M, et al. Neurological soft signs in schizophrenia. Schizophr. Res. 1991;6:25–30
  54. Shibre T, Kebede D, Alem A, Kebreab S, Melaku Z, Deyassa N, et al. Neurological soft signs (NSS) in 200 treatment-naive cases with schizophrenia: a community-based study in a rural setting. Nord. J. Psychiatry. 2002;56:425–431
  55. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970;212(Suppl):11–19
  56. Venkatasubramanian G, Latha V, Gangadhar BN, Janakiramaiah N, Subbakrishna DK, Jayakumar PN, et al. Neurological soft signs in never-treated schizophrenia. Acta Psychiatr. Scand. 2003;108:144–146
  57. Whitty P, Clarke M, Browne S, McTigue O, Kamali M, Feeney L, et al. Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol. Med. 2003;33:1479–1484
  58. Wong AH, Voruganti LN, Heslegrave RJ, Awad AG. Neurocognitive deficits and neurological signs in schizophrenia. Schizophr. Res. 1997;23:139–146
  59. Yazici AH, Demir B, Yazici KM, Gogus A. Neurological soft signs in schizophrenic patients and their nonpsychotic siblings. Schizophr. Res. 2002;58:241–246

PII: S0920-9964(04)00211-7

doi: 10.1016/j.schres.2004.06.014

Schizophrenia Research
Volume 75, Issue 1 , Pages 35-44 , 1 June 2005

Article Tools